Small molecules in anti-angiogenic therapy

Raffaella Giavazzi, Maria Ines Nicoletti

Research output: Contribution to journalArticle

Abstract

Angiogenesis, or the formation of new blood vessels from pre-existing capillaries, is a sequence of events that occurs in many physiological and pathological conditions, including cancer. The identification of several pro-angiogenic factors and the recent description of endogenous inhibitors of angiogenesis, has made interference with vessel formation an attractive potential therapeutic option. Several compounds with anti-angiogenic or antivascular properties have been identified, and several of them have entered patient studies in cancer on the basis of promising preclinical results. However, this development of compounds that are not directly cytotoxic to cancer cells is problematic in terms of trial design and interpretation. This review discusses classes of molecules that interfere specifically with regulatory elements of the angiogenic process, and comments upon their stage of development and characteristics in clinical trials.

Original languageEnglish
Pages (from-to)482-491
Number of pages10
JournalCurrent Opinion in Investigational Drugs
Volume3
Issue number3
Publication statusPublished - 2002

Fingerprint

Neoplasms
Angiogenesis Inhibitors
Angiogenesis Inducing Agents
Blood Vessels
Therapeutics
Clinical Trials

Keywords

  • Angiogenesis
  • Cancer
  • Endothelial cells
  • Growth factors
  • Integrins
  • Matrix metalloproteinases

ASJC Scopus subject areas

  • Pharmacology

Cite this

Small molecules in anti-angiogenic therapy. / Giavazzi, Raffaella; Nicoletti, Maria Ines.

In: Current Opinion in Investigational Drugs, Vol. 3, No. 3, 2002, p. 482-491.

Research output: Contribution to journalArticle

Giavazzi, Raffaella ; Nicoletti, Maria Ines. / Small molecules in anti-angiogenic therapy. In: Current Opinion in Investigational Drugs. 2002 ; Vol. 3, No. 3. pp. 482-491.
@article{ee080fbe9f9a4b2baed31162375c0de9,
title = "Small molecules in anti-angiogenic therapy",
abstract = "Angiogenesis, or the formation of new blood vessels from pre-existing capillaries, is a sequence of events that occurs in many physiological and pathological conditions, including cancer. The identification of several pro-angiogenic factors and the recent description of endogenous inhibitors of angiogenesis, has made interference with vessel formation an attractive potential therapeutic option. Several compounds with anti-angiogenic or antivascular properties have been identified, and several of them have entered patient studies in cancer on the basis of promising preclinical results. However, this development of compounds that are not directly cytotoxic to cancer cells is problematic in terms of trial design and interpretation. This review discusses classes of molecules that interfere specifically with regulatory elements of the angiogenic process, and comments upon their stage of development and characteristics in clinical trials.",
keywords = "Angiogenesis, Cancer, Endothelial cells, Growth factors, Integrins, Matrix metalloproteinases",
author = "Raffaella Giavazzi and Nicoletti, {Maria Ines}",
year = "2002",
language = "English",
volume = "3",
pages = "482--491",
journal = "Current Opinion in Investigational Drugs",
issn = "1472-4472",
publisher = "Current Drugs Ltd.",
number = "3",

}

TY - JOUR

T1 - Small molecules in anti-angiogenic therapy

AU - Giavazzi, Raffaella

AU - Nicoletti, Maria Ines

PY - 2002

Y1 - 2002

N2 - Angiogenesis, or the formation of new blood vessels from pre-existing capillaries, is a sequence of events that occurs in many physiological and pathological conditions, including cancer. The identification of several pro-angiogenic factors and the recent description of endogenous inhibitors of angiogenesis, has made interference with vessel formation an attractive potential therapeutic option. Several compounds with anti-angiogenic or antivascular properties have been identified, and several of them have entered patient studies in cancer on the basis of promising preclinical results. However, this development of compounds that are not directly cytotoxic to cancer cells is problematic in terms of trial design and interpretation. This review discusses classes of molecules that interfere specifically with regulatory elements of the angiogenic process, and comments upon their stage of development and characteristics in clinical trials.

AB - Angiogenesis, or the formation of new blood vessels from pre-existing capillaries, is a sequence of events that occurs in many physiological and pathological conditions, including cancer. The identification of several pro-angiogenic factors and the recent description of endogenous inhibitors of angiogenesis, has made interference with vessel formation an attractive potential therapeutic option. Several compounds with anti-angiogenic or antivascular properties have been identified, and several of them have entered patient studies in cancer on the basis of promising preclinical results. However, this development of compounds that are not directly cytotoxic to cancer cells is problematic in terms of trial design and interpretation. This review discusses classes of molecules that interfere specifically with regulatory elements of the angiogenic process, and comments upon their stage of development and characteristics in clinical trials.

KW - Angiogenesis

KW - Cancer

KW - Endothelial cells

KW - Growth factors

KW - Integrins

KW - Matrix metalloproteinases

UR - http://www.scopus.com/inward/record.url?scp=0036231941&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036231941&partnerID=8YFLogxK

M3 - Article

C2 - 12054101

AN - SCOPUS:0036231941

VL - 3

SP - 482

EP - 491

JO - Current Opinion in Investigational Drugs

JF - Current Opinion in Investigational Drugs

SN - 1472-4472

IS - 3

ER -